These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 27070712)

  • 1. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
    Hunter FW; Wouters BG; Wilson WR
    Br J Cancer; 2016 May; 114(10):1071-7. PubMed ID: 27070712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
    Phillips RM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.
    Su MX; Zhang LL; Huang ZJ; Shi JJ; Lu JJ
    Curr Drug Targets; 2019; 20(6):668-678. PubMed ID: 30468124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of hypoxia-activated prodrugs in cancer therapy.
    Denny WA
    Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting hypoxia in cancer therapy.
    Wilson WR; Hay MP
    Nat Rev Cancer; 2011 Jun; 11(6):393-410. PubMed ID: 21606941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
    Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
    Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
    Denny WA
    Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.
    Wang J; Guise CP; Dachs GU; Phung Y; Hsu AH; Lambie NK; Patterson AV; Wilson WR
    Biochem Pharmacol; 2014 Oct; 91(4):436-46. PubMed ID: 25130546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 - 2021.
    Anduran E; Dubois LJ; Lambin P; Winum JY
    Expert Opin Ther Pat; 2022 Jan; 32(1):1-12. PubMed ID: 34241566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
    Wilson WR; Tercel M; Anderson RF; Denny WA
    Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs.
    Jackson RK; Liew LP; Hay MP
    Clin Oncol (R Coll Radiol); 2019 May; 31(5):290-302. PubMed ID: 30853148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia: targeting the tumour.
    Boyle RG; Travers S
    Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing.
    Wilson WR; Pruijn FB
    Clin Exp Pharmacol Physiol; 1995 Nov; 22(11):881-5. PubMed ID: 8593750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
    Patterson LH; McKeown SR
    Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumors with hypoxia-activated cytotoxins.
    Ahn GO; Brown M
    Front Biosci; 2007 May; 12():3483-501. PubMed ID: 17485316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel multifunctional 2-nitroimidazole-based bioreductive linker and its application in hypoxia-activated prodrugs.
    Huang Y; Jin C; Yu J; Wang L; Lu W
    Bioorg Chem; 2020 Aug; 101():103975. PubMed ID: 32474180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancements in the development of HIF-1α-activated protein switches for use in enzyme prodrug therapy.
    Wright RC; Khakhar A; Eshleman JR; Ostermeier M
    PLoS One; 2014; 9(11):e114032. PubMed ID: 25426963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
    Hunter FW; Jaiswal JK; Hurley DG; Liyanage HD; McManaway SP; Gu Y; Richter S; Wang J; Tercel M; Print CG; Wilson WR; Pruijn FB
    Biochem Pharmacol; 2014 May; 89(2):224-35. PubMed ID: 24632291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
    Hunter FW; Young RJ; Shalev Z; Vellanki RN; Wang J; Gu Y; Joshi N; Sreebhavan S; Weinreb I; Goldstein DP; Moffat J; Ketela T; Brown KR; Koritzinsky M; Solomon B; Rischin D; Wilson WR; Wouters BG
    Cancer Res; 2015 Oct; 75(19):4211-23. PubMed ID: 26297733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.